Ocugen (OCGN) EGM 2026 summary
Event summary combining transcript, slides, and related documents.
EGM 2026 summary
21 Sep, 2026Opening remarks and agenda
Meeting called to order and held virtually to maximize stockholder participation.
Introduction of board members and executive management present.
Agenda and rules of conduct made available on the virtual meeting website.
Specific resolutions to be voted on
Proposal to amend the Charter to increase authorized common stock by 250 million shares.
Proposal to approve adjournment of the meeting to solicit additional proxies if needed.
Corporate governance
Quorum established with at least one-third of voting power represented.
Independent inspector appointed to oversee voting and proxies.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Ocugen
- Late-stage gene therapies for major eye diseases advance toward BLA filings, with cash runway into 2028.OCGN
H.C. Wainwright 28th Annual Global Investment Conference - Shareholders will vote to increase authorized shares to support growth and commercialization.OCGNProxy filing
- Pivotal gene therapy trials for RP and Stargardt aim for global launches by 2028.OCGNCanaccord Genuity's 46th Annual Growth Conference
- FDA cleared OCU410 phase III; $130M financing extends cash runway to 2028 amid going concern risk.OCGNQ2 2026
- Vote on a 250 million share increase and meeting adjournment is recommended for approval.OCGNProxy filing
- Vote sought to increase authorized shares by 250M to support growth and strategic flexibility.OCGNProxy filing
- Vote sought to increase authorized shares by 250 million to support growth and financing flexibility.OCGNProxy filing
- Late-stage gene therapies for major retinal diseases advance toward global approvals by 2028.OCGNPiper Sandler Virtual Ophthalmology Day
- Gene therapy trials advanced, net loss narrowed, and $32.6M raised to extend cash runway.OCGNQ2 2024